Stifel resumed coverage of Tandem Diabetes (TNDM) with a Hold rating and $15 price target The firm is concerned about the company’s sequential ...

Earlier this year, Tandem Diabetes Care announced a voluntary correction for certain t:slim X2 insulin pumps after identifying a potential defect that could interrupt insulin delivery and pose health ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...

Truist analyst Richard Newitter raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $14 and keeps a Hold rating on the shares as ...

On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near.

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID ...

SAN DIEGO, September 29, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump ...

The t:slim X2 automated insulin delivery system with Control IQ+ technology. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received approval to ...